Lacosamide PCD Pharma Franchise Company

Cafoli Lifecare is a trusted Lacosamide PCD pharma franchise company offering 5 formulations in tablet and injection forms. Manufactured at WHO-GMP certified facilities, this range gives franchise partners a modern, well-tolerated antiepileptic for the growing neurology segment.

What is Lacosamide?

Lacosamide is a third-generation antiepileptic drug. It selectively enhances the slow inactivation of voltage-gated sodium channels, stabilising hyperexcitable neuronal membranes and reducing repetitive neuronal firing without affecting fast inactivation. This distinct mechanism gives it a favourable efficacy-and-tolerability balance and low interaction potential. Learn more on PubChem.

Therapeutic Applications of Lacosamide

Lacosamide is indicated for the treatment of partial-onset (focal) seizures, as monotherapy or adjunctive therapy, with the intravenous form allowing continuity of treatment when oral dosing is not possible. It is prescribed mainly by neurologists and epileptologists.

Why Lacosamide is a High-Potential Molecule for Distributors

Epilepsy management in India is steadily shifting toward newer, better-tolerated antiepileptics with fewer drug interactions, and lacosamide fits this trend as a preferred add-on and monotherapy option. The availability of both oral and IV forms supports seamless hospital-to-home therapy, giving distributors a premium, specialist-driven neurology molecule with recurring, long-term prescription demand.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers exclusive district-wise monopoly rights, WHO-GMP certified and DCGI-approved formulations, attractive promotional inputs and marketing support, and the reliability of a network trusted by 1000+ franchise partners across India.

References

1. PubChem – Lacosamide Compound Summary, U.S. National Library of Medicine
2. PubMed – Clinical literature on Lacosamide